Why have clinical trials in sepsis failed?

Trends in Molecular Medicine

Volumn 20, Issue 4, 2014, Pages 195-203

  Marshall, John C ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adjuvant therapy; Biologic response modifier; Clinical trials; Innate immunity; Intensive care; Sepsis; Septic shock; Staging

Indexed keywords

ALKALINE PHOSPHATASE; ANTITHROMBIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BRADYKININ ANTAGONIST; CORTICOSTEROID; ERITORAN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; LACTOFERRIN; LIPID EMULSION; METHYLENE BLUE; MONOCLONAL ANTIBODY; N(G) METHYLARGININE; PHOSPHOLIPASE A2 INHIBITOR; POLYCLONAL ANTIBODY; POLYMYXIN B; RESATORVID; SELENIUM; TAUROLIDINE; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; VASOPRESSIN;

ARTIFICIAL VENTILATION; BREATHING RATE; DISEASE COURSE; DISEASE MODEL; ENDOTOXEMIA; HEART RATE; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTEGRATION; LANDSCAPE; LETHALITY; MEDICAL RESEARCH; NONHUMAN; PATIENT CODING; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADJUVANT THERAPY; BIOLOGIC RESPONSE MODIFIER; CLINICAL TRIALS; INNATE IMMUNITY; INTENSIVE CARE; SEPSIS; SEPTIC SHOCK; STAGING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; SEPSIS; TREATMENT OUTCOME;

EID: 84897377065     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.01.007     Document Type: Review

References (53)

1. Schumer W. Steroids in the treatment of septic shock. Ann. Surg. 1976, 184:333-341.
2. Fink M.P. Another negative clinical trial of a new agent for the treatment of sepsis: rethinking the process of developing adjuvant treatments for serious infections. Crit. Care Med. 1995, 23:989-991.
3. Wenzel R.P., Edmond M.B. Septic shock - evaluating another failed treatment. N. Engl. J. Med. 2012, 366:2122-2124.
4. Bone R.C., et al. Sepsis syndrome: a valid clinical entity. Crit. Care Med. 1989, 17:389-393.
5. Marshall J.C. Sepsis: rethinking the approach to clinical research. J. Leukoc. Biol. 2008, 83:471-482.
6. Centers for Disease Control and Prevention Achievements in public health, 1900-1999. MMWR 1999, 48:621-629.
7. Atkins E., Wood W.B. Studies on the pathogenesis of fever. II. Identification of an endogenous pyrogen in the blood stream following the injection of typhoid vaccine. J. Exp. Med. 1955, 102:499-516.
8. Michalek S.M., et al. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J. Infect. Dis. 1980, 141:55-63.
9. Dinarello C.A. Interleukin-1. Rev. Infect. Dis. 1984, 6:51-95.
10. Tracey K.J., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987, 330:662-664.
11. Esmon C.T. Coagulation and inflammation. J. Endotoxin Res. 2003, 9:192-198.
12. Poltorak A., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in the Tlr4 gene. Science 1998, 282:2085-2088.
13. Marshall J.C., Sweeney D. Microbial infection and the septic response in critical surgical illness. Arch. Surg. 1990, 125:17-23.
14. Marshall J.C. Lipopolysaccharide: an endotoxin or an exogenous hormone?. Clin. Infect. Dis. 2005, 41(Suppl. 7):S470-S480.
15. Marshall J.C. Such stuff as dreams are made on: mediator-targeted therapy in sepsis. Nat. Rev. Drug Discov. 2003, 2:391-405.
16. Calvano S.E., et al. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037.
17. Bone R.C., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101:1644-1655.
18. Ziegler E.J., et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 1982, 307:1225-1230.
19. Angus D.C., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29:1303-1310.
20. Casey L.C., et al. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 1993, 119:771-778.
21. Panacek E.A., et al. Efficacy and safety of the monoclonal anti-TNF antibody F(ab')2 fragment in patients with severe sepsis stratified by IL-6 level. Crit. Care Med. 2004, 32:2173-2182.
22. Sorenson T.I., et al. Genetic and environmental influences on premature death in adult adoptees. N. Engl. J. Med. 1988, 318:727-732.
23. Lorente J.A., Marshall J.C. Neutralization of tumor necrosis factor (TNF) in pre-clinical models of sepsis. Shock 2005, 24(Suppl. 1):107-119.
24. McCloskey R.V., et al. The CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized double-blind, placebo-controlled trial. Ann. Intern. Med. 1994, 121:1-5.
25. Opal S.M., et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013, 309:1154-1162.
26. Bernard G.R., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 2001, 344:699-709.
27. Ziegler E.J., et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N. Engl. J. Med. 1991, 324:429-436.
28. Baumgartner J.D., et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor α and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J. Exp. Med. 1990, 171:889-896.
29. Abraham E., et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998, 351:929-933.
30. Opal S.M., et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. 1997, 25:1115-1124.
31. Ranieri V.M., et al. Drotrecogin α (activated) in adults with septic shock. N. Engl. J. Med. 2012, 366:2055-2064.
32. Lopez A., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 2004, 32:21-30.
33. Siegel J.P. Biotechnology and clinical trials. J. Infect. Dis. 2002, 185(Suppl. 1):S52-S57.
34. Finfer S., et al. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 2009, 360:1283-1297.
35. Reinhart K., et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit. Care Med. 1996, 24:733-742.
36. Marshall J.C., Reinhart K. International Sepsis Forum. Biomarkers of sepsis. Crit. Care Med. 2009, 37:2290-2298.
37. Perl T.M., et al. Long-term survival and function after suspected Gram-negative sepsis. JAMA 1995, 274:338-345.
38. Herridge M.S., et al. Functional disability 5 years after acute respiratory distress syndrome. N. Engl. J. Med. 2011, 364:1293-1304.
39. Levin M., et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet 2000, 356:961-967.
40. Rivers E., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001, 345:1368-1377.
41. Levy M.M., et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit. Care Med. 2010, 38:367-374.
42. Rivers E.P., et al. Early biomarker activity in severe sepsis and septic shock and a contemporary review of immunotherapy trials: not a time to give up, but to give it earlier. Shock 2013, 39:127-137.
43. Majno G. The ancient riddle of sigma eta psi iota sigma (sepsis). J. Infect. Dis. 1991, 163:937-945.
44. Levy M.M., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 2003, 34:1250-1256.
45. Kaczorowski D.J., et al. Early events in the recognition of danger signals after tissue injury. J. Leukoc. Biol. 2008, 83:546-552.
46. Xiao W., et al. A genomic storm in critically injured humans. J. Exp. Med. 2011, 208:2581-2590.
47. Aaltonen K.J., et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 2012, 7:e30275.
48. Winthrop K.L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Pract. Rheumatol. 2006, 2:602-610.
49. Seok J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:3507-3512.
50. Kannel W.B. The Framingham Study: its 50-year legacy and future promise. J. Atheroscler. Thromb. 2000, 6:60-66.
51. Hayes D.F., et al. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 2007, 357:1496-1506.
52. Marshall J.C. The PIRO (Predisposition, Insult, Response, Organ Dysfunction) model: towards a staging system for acute illness. Virulence 2014, 5:27-35.
53. InFACT: a global critical care research response to H1N1. Lancet 2010, 375:11-13. The InFACT Global H1N1 Collaboration.